BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 24833028)

  • 1. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.
    Lecavalier-Barsoum M; Quon H; Abdulkarim B
    Cochrane Database Syst Rev; 2014 May; 2014(5):CD007104. PubMed ID: 24833028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas.
    Quon H; Abdulkarim B
    Cochrane Database Syst Rev; 2008 Apr; (2):CD007104. PubMed ID: 18425979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.
    van den Bent MJ; Carpentier AF; Brandes AA; Sanson M; Taphoorn MJ; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Haaxma-Reiche H; Kros JM; van Kouwenhoven MC; Vecht CJ; Allgeier A; Lacombe D; Gorlia T
    J Clin Oncol; 2006 Jun; 24(18):2715-22. PubMed ID: 16782911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.
    van den Bent MJ; Dubbink HJ; Sanson M; van der Lee-Haarloo CR; Hegi M; Jeuken JW; Ibdaih A; Brandes AA; Taphoorn MJ; Frenay M; Lacombe D; Gorlia T; Dinjens WN; Kros JM
    J Clin Oncol; 2009 Dec; 27(35):5881-6. PubMed ID: 19901104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.
    ; Cairncross G; Berkey B; Shaw E; Jenkins R; Scheithauer B; Brachman D; Buckner J; Fink K; Souhami L; Laperierre N; Mehta M; Curran W
    J Clin Oncol; 2006 Jun; 24(18):2707-14. PubMed ID: 16782910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951.
    Gorlia T; Delattre JY; Brandes AA; Kros JM; Taphoorn MJ; Kouwenhoven MC; Bernsen HJ; Frénay M; Tijssen CC; Lacombe D; van den Bent MJ
    Eur J Cancer; 2013 Nov; 49(16):3477-85. PubMed ID: 23896377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and prognostic value of molecular markers.
    Minniti G; Arcella A; Scaringi C; Lanzetta G; Di Stefano D; Scarpino S; Pace A; Giangaspero F; Osti MF; Enrici RM
    J Neurooncol; 2014 Jan; 116(2):275-82. PubMed ID: 24162810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.
    van den Bent MJ; Brandes AA; Taphoorn MJ; Kros JM; Kouwenhoven MC; Delattre JY; Bernsen HJ; Frenay M; Tijssen CC; Grisold W; Sipos L; Enting RH; French PJ; Dinjens WN; Vecht CJ; Allgeier A; Lacombe D; Gorlia T; Hoang-Xuan K
    J Clin Oncol; 2013 Jan; 31(3):344-50. PubMed ID: 23071237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131.
    Vogelbaum MA; Berkey B; Peereboom D; Macdonald D; Giannini C; Suh JH; Jenkins R; Herman J; Brown P; Blumenthal DT; Biggs C; Schultz C; Mehta M
    Neuro Oncol; 2009 Apr; 11(2):167-75. PubMed ID: 18779504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
    Speirs CK; Simpson JR; Robinson CG; DeWees TA; Tran DD; Linette G; Chicoine MR; Dacey RG; Rich KM; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):268-76. PubMed ID: 25636755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiotherapy Plus Procarbazine, Lomustine, and Vincristine Versus Radiotherapy Plus Temozolomide for IDH-Mutant Anaplastic Astrocytoma: A Retrospective Multicenter Analysis of the French POLA Cohort.
    Esteyrie V; Dehais C; Martin E; Carpentier C; Uro-Coste E; Figarella-Branger D; Bronniman C; Pouessel D; Ciron DL; Ducray F; Moyal EC; Network P
    Oncologist; 2021 May; 26(5):e838-e846. PubMed ID: 33524191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: A report from EORTC study 26951.
    Kouwenhoven MC; Gorlia T; Kros JM; Ibdaih A; Brandes AA; Bromberg JE; Mokhtari K; van Duinen SG; Teepen JL; Wesseling P; Vandenbos F; Grisold W; Sipos L; Mirimanoff R; Vecht CJ; Allgeier A; Lacombe D; van den Bent MJ
    Neuro Oncol; 2009 Dec; 11(6):737-46. PubMed ID: 19224764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-deletion of 1p/19q as Prognostic and Predictive Biomarker for Patients in West Bohemia with Anaplastic Oligodendroglioma.
    Polivka J; Polivka J; Repik T; Rohan V; Hes O; Topolcan O
    Anticancer Res; 2016 Jan; 36(1):471-6. PubMed ID: 26722084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
    Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
    Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
    Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-grade and anaplastic oligodendroglioma.
    Van Den Bent MJ; Bromberg JE; Buckner J
    Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment recommendations for anaplastic oligodendrogliomas that are codeleted.
    Anderson MD; Gilbert MR
    Oncology (Williston Park); 2013 Apr; 27(4):315-20, 322. PubMed ID: 23781695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
    Prados MD; Seiferheld W; Sandler HM; Buckner JC; Phillips T; Schultz C; Urtasun R; Davis R; Gutin P; Cascino TL; Greenberg HS; Curran WJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1147-52. PubMed ID: 15001257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.
    Roth P; Wick W; Weller M
    Curr Treat Options Oncol; 2013 Dec; 14(4):505-13. PubMed ID: 23907441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.